In the phase II global study [80], alectinib at the dose of 600 mg taken twice a day showed an impressive activity in patients with advanced crizotinib-refractory ALK positive NSCLC, in particular in patients with CNS metastases. The gene discussed is ALK; the disease is non-small cell lung carcinoma.